Literature DB >> 24958853

Activation of Ras overcomes B-cell tolerance to promote differentiation of autoreactive B cells and production of autoantibodies.

Lenka S Teodorovic1, Chiara Babolin1, Sarah L Rowland1, Sarah A Greaves1, David P Baldwin1, Raul M Torres1, Roberta Pelanda2.   

Abstract

Newly generated immature B cells are selected to enter the peripheral mature B-cell pool only if they do not bind (or bind limited amount of) self-antigen. We previously suggested that this selection relies on basal extracellular signal-regulated kinase (Erk) activation mediated by tonic B-cell antigen receptor (BCR) signaling and that this signal can be replaced by an active rat sarcoma (Ras), which are small GTPase proteins. In this study we compared the activity of Ras and Erk in nonautoreactive and autoreactive immature B cells and investigated whether activation of Ras can break tolerance. Our results demonstrate lower levels of active Erk and Ras in autoreactive immature B cells, although this is evident only when these cells display medium/high avidity for self-antigen. Basal activation of Erk in immature B cells is proportional to surface IgM and dependent on sarcoma family kinases, whereas it is independent of B-cell activating factor, IFN, and Toll-like receptor signaling. Ectopic expression of the constitutively active mutant Ras form N-RasD12 in autoreactive cells raises active Erk, halts receptor editing via PI3 kinase, and promotes differentiation via Erk, breaking central tolerance. Moreover, when B cells coexpress autoreactive and nonautoreactive BCRs, N-RasD12 leads also to a break in peripheral tolerance with the production of autoantibodies. Our findings indicate that in immature B cells, basal activation of Ras and Erk are controlled by tonic BCR signaling, and that positive changes in Ras activity can lead to a break in both central and peripheral B-cell tolerance.

Entities:  

Keywords:  BAFF; Src

Mesh:

Substances:

Year:  2014        PMID: 24958853      PMCID: PMC4103347          DOI: 10.1073/pnas.1402159111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  63 in total

1.  B cell receptor expression level determines the fate of developing B lymphocytes: receptor editing versus selection.

Authors:  V Kouskoff; G Lacaud; K Pape; M Retter; D Nemazee
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

2.  Receptor editing is the main mechanism of B cell tolerance toward membrane antigens.

Authors:  Regina Halverson; Raul M Torres; Roberta Pelanda
Journal:  Nat Immunol       Date:  2004-05-23       Impact factor: 25.606

3.  Developmental regulation of B lymphocyte immune tolerance compartmentalizes clonal selection from receptor selection.

Authors:  D Melamed; R J Benschop; J C Cambier; D Nemazee
Journal:  Cell       Date:  1998-01-23       Impact factor: 41.582

4.  Negative selection of multireactive B cell clones in normal adult mice.

Authors:  A Grandien; R Fucs; A Nobrega; J Andersson; A Coutinho
Journal:  Eur J Immunol       Date:  1994-06       Impact factor: 5.532

5.  T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-alpha.

Authors:  Yuanyuan Zha; Reinhard Marks; Allen W Ho; Amy C Peterson; Sujit Janardhan; Ian Brown; Kesavannair Praveen; Stacey Stang; James C Stone; Thomas F Gajewski
Journal:  Nat Immunol       Date:  2006-10-08       Impact factor: 25.606

6.  Dependence of Wilms tumor cells on signaling through insulin-like growth factor 1 in an orthotopic xenograft model targetable by specific receptor inhibition.

Authors:  Aleksandra Bielen; Gary Box; Lara Perryman; Lynn Bjerke; Sergey Popov; Yann Jamin; Alexa Jury; Melanie Valenti; Alexis de Haven Brandon; Vanessa Martins; Vincent Romanet; Sebastien Jeay; Florence I Raynaud; Francesco Hofmann; Simon P Robinson; Suzanne A Eccles; Chris Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-23       Impact factor: 11.205

Review 7.  Class II cytokine receptors and their ligands: key antiviral and inflammatory modulators.

Authors:  Jean-Christophe Renauld
Journal:  Nat Rev Immunol       Date:  2003-08       Impact factor: 53.106

8.  Erk kinases link pre-B cell receptor signaling to transcriptional events required for early B cell expansion.

Authors:  Tomoharu Yasuda; Hideki Sanjo; Gilles Pagès; Yohei Kawano; Hajime Karasuyama; Jacques Pouysségur; Masato Ogata; Tomohiro Kurosaki
Journal:  Immunity       Date:  2008-03-20       Impact factor: 31.745

9.  BCR mutants deficient in ligand-independent and more sensitive for ligand-dependent signaling.

Authors:  Catrin Pracht; Kerstin Gimborn; Michael Reth; Michael Huber
Journal:  Eur J Immunol       Date:  2002-06       Impact factor: 5.532

10.  Murine B cell development and antibody responses to model antigens are not impaired in the absence of the TNF receptor GITR.

Authors:  Lenka Sinik Teodorovic; Carlo Riccardi; Raul M Torres; Roberta Pelanda
Journal:  PLoS One       Date:  2012-02-06       Impact factor: 3.240

View more
  17 in total

1.  Administration of activated lymphocyte-derived DNA accelerates and aggravates lupus nephritis in B6/lpr mice: a new approach to modify a lupus murine model.

Authors:  Y Zhu; Y Yue; S Xiong
Journal:  Clin Exp Immunol       Date:  2018-07-23       Impact factor: 4.330

Review 2.  Autoimmunity checkpoints as therapeutic targets in B cell malignancies.

Authors:  Markus Müschen
Journal:  Nat Rev Cancer       Date:  2018-01-05       Impact factor: 60.716

Review 3.  Mechanisms of central tolerance for B cells.

Authors:  David Nemazee
Journal:  Nat Rev Immunol       Date:  2017-04-03       Impact factor: 53.106

4.  Altered toll-like receptor responsiveness underlies a dominant heritable defect in B cell tolerance in autoimmune New Zealand Black mice.

Authors:  Amy G Clark; Elizabeth S Buckley; Mary H Foster
Journal:  Eur J Immunol       Date:  2018-01-19       Impact factor: 5.532

Review 5.  JMML and RALD (Ras-associated autoimmune leukoproliferative disorder): common genetic etiology yet clinically distinct entities.

Authors:  Katherine R Calvo; Susan Price; Raul C Braylan; Joao Bosco Oliveira; Michael Lenardo; Thomas A Fleisher; V Koneti Rao
Journal:  Blood       Date:  2015-02-17       Impact factor: 22.113

Review 6.  B-cell intrinsic and extrinsic signals that regulate central tolerance of mouse and human B cells.

Authors:  Roberta Pelanda; Sarah A Greaves; Thiago Alves da Costa; Lena M Cedrone; Margaret L Campbell; Raul M Torres
Journal:  Immunol Rev       Date:  2022-01-08       Impact factor: 12.988

7.  LAPTM5 mediates immature B cell apoptosis and B cell tolerance by regulating the WWP2-PTEN-AKT pathway.

Authors:  Ying Wang; Jun Liu; Chizuru Akatsu; Runyun Zhang; Hai Zhang; Han Zhu; Kangwei Liu; Han-Ying Zhu; Qing Min; Xin Meng; Chaoqun Cui; Yue Tang; Meiping Yu; Yaxuan Li; Xiaoqian Feng; Hao Wei; Zichao Wen; Sihan Ji; Martin G Weigert; Takeshi Tsubata; Ji-Yang Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-29       Impact factor: 12.779

8.  The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3β inhibition.

Authors:  Gabriele Varano; Simon Raffel; Martina Sormani; Federica Zanardi; Silvia Lonardi; Christin Zasada; Laura Perucho; Valentina Petrocelli; Andrea Haake; Albert K Lee; Mattia Bugatti; Ulrike Paul; Eelco Van Anken; Laura Pasqualucci; Raul Rabadan; Reiner Siebert; Stefan Kempa; Maurilio Ponzoni; Fabio Facchetti; Klaus Rajewsky; Stefano Casola
Journal:  Nature       Date:  2017-05-31       Impact factor: 49.962

9.  Central human B cell tolerance manifests with a distinctive cell phenotype and is enforced via CXCR4 signaling in hu-mice.

Authors:  Thiago Alves da Costa; Jacob N Peterson; Julie Lang; Jeremy Shulman; Xiayuan Liang; Brian M Freed; Susan A Boackle; Pilar Lauzurica; Raul M Torres; Roberta Pelanda
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-20       Impact factor: 11.205

Review 10.  MicroRNA regulation of B cell receptor signaling.

Authors:  Timothy C Borbet; Marcus J Hines; Sergei B Koralov
Journal:  Immunol Rev       Date:  2021-09-14       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.